Dropbox Inc vs GeneDx Holdings Corp — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Dropbox Inc is far larger — about 3.7× GeneDx Holdings Corp's market cap, and Dropbox Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and GeneDx Holdings Corp for 19 Days on average.
| DBX | WGS | |
|---|---|---|
Market Cap | $7.42B | $2.02B |
Volume | 3,061,580 | 734,640 |
Sector | Technology | Health |
52-Week High | $37.74 | $167.51 |
52-Week Low | $22.06 | $34.51 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $10.29B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% today, showing bearish technical signals with resistance at $34. Fundamentally, the company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights insider selling and a security breach affecting 5,000 accounts in August 2026, while analyst sentiment remains divided with a consensus price target of $26.83.
The outlook remains cautious due to mixed analyst ratings and insider selling activity. While strong cash flow generation and consistent earnings beats provide support, valuation concerns and stagnant revenue growth near $2.5B present headwinds. Key risks include competitive pressures in cloud storage and execution challenges in maintaining market position.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →